Successful Dose De-Escalation of Infliximab in Rheumatoid Arthritis Patients with Stable Low Disease Activity and Treatment

被引：0
|
作者：
van der Maas, Aatke
den Broeder, Alfons
van den Hoogen, Frank H. J. [1 ]
Van Riel, Piet [2 ]
van den Bemt, Bart J. F.
机构：
[1] Sint Maartensklini, Dept Rheumatol, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1700
引用
收藏
页码：S666 / S666
页数：1
相关论文
共 50 条
  • [31] Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity
    van Herwaarden, N.
    Herfkens-Hol, S.
    van der Maas, A.
    van den Bemt, B. J. F.
    van Vollenhoven, R. F.
    Bijlsma, J. W. J.
    den Broeder, A. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (03) : 390 - 394
  • [32] Dose Escalation Among Rheumatoid Arthritis Patients Treated with Infliximab or Abatacept: Comparison in Claims Data
    Darkow, Theodore
    Chastek, Benjamin
    Rosenblatt, Lisa
    Trivedi, Digisha
    Hebden, Tony
    Henk, Henry
    Liu, Fang
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S476 - S476
  • [33] INFLIXIMAB DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION IS SAFE AND WELL TOLERATED
    Allegretti, Jessica R.
    McClure, Emma L.
    Marcus, Jenna
    Norton, Beth Ann
    Hamilton, Matthew
    Winter, Rachel
    De Silva, Punyanganie
    Friedman, Sonia
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2020, 158 (06) : S461 - S461
  • [34] Dose intensification with infliximab in patients with rheumatoid arthritis
    Berger, A
    Edelsberg, J
    Li, TT
    Maclean, JR
    Oster, G
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (12) : 2021 - 2025
  • [35] Successful dose de-escalation to adalimumab 40mg every three weeks in patients with Crohn's disease
    Ferrante, M.
    Van Steenbergen, S.
    Bian, S.
    Ballet, V.
    Vermeire, S.
    Van Assche, G.
    Gils, A.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S331 - S331
  • [36] Dose optimization of infliximab in patients with rheumatoid arthritis
    Alten, Rieke
    van den Bosch, Filip
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2014, 17 (01) : 5 - 18
  • [37] SUCCESSFUL DOSE DE-ESCALATION TO ADALIMUMAB 40MG EVERY THREE WEEKS IN PATIENTS WITH CROHN'S DISEASE
    Ferrante, Marc
    Van Steenbergen, Sophie
    Bian, Sumin
    Ballet, Vera
    Vermeire, Severine
    Van Assche, Gert A.
    Gils, Ann
    GASTROENTEROLOGY, 2017, 152 (05) : S406 - S407
  • [38] COMPARISON OF DOSE ESCALATION OF INFLIXIMAB AND THE ADDITION OF TACROLIMUS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO INFLIXIMAB AND METHOTREXATE COMBINATION THERAPY
    Yonemoto, Y.
    Okamura, K.
    Kaneko, T.
    Kobayashi, T.
    Takagishi, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 199 - 200
  • [39] Biologic De-Escalation in Rheumatoid Arthritis: Cost Savings and Clinical Success.
    Sharma, Tarun S.
    Kirillova, Lyudmila
    Berger, Andrea
    Newman, Eric D.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S418 - S418
  • [40] Dose Reduction Of Tocilizumab In Rheumatoid Arthritis Patients With Low Disease Activity Is Feasible
    van Herwaarden, Noortje
    Herfkens-Hol, Susan
    van der Maas, Aatke
    van Den Bemt, Bart J. F.
    van Vollenhoven, Ronald F.
    Bijlsma, Johannes W. J.
    den Broeder, Alfons A.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S992 - S992
12345